HC Wainwright reissued their buy rating on shares of Kymera Therapeutics ( NASDAQ:KYMR – Free Report ) in a research report report published on Friday morning, Benzinga reports. The brokerage currently has a $85.00 target price on the stock. KYMR has been the subject of several other reports. Truist Financial started coverage on Kymera Therapeutics in a research note on Friday, June 30th. They set a buy rating and a $50.00 price objective for the company. Raymond James raised Kymera Therapeutics from a market perform rating to an outperform rating in a research note on Thursday, May 4th.

https://www.dailypolitical.com/2023/08/05/kymera-therapeutics-nasdaqkymr-given-buy-rating-at-hc-wainwright.html

#dailypolitical